REFERENCES
1. Méndez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I-II study. Acta Oncol 2006;45:831-7.
2. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013;31:1631-9.
3. Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 2014;111:412-7.
4. Andratschke N, Alheid H, Allgäuer M, Becker G, Blanck O, et al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer 2018;18:283.
5. Scorsetti M, Comito T, Clerici E, Franzese C, Tozzi A, et al. Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up. Radiat Oncol 2018;13:234.
6. Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol 2017;67:92-9.
7. Fajardo LF. The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol 2005;44:13-22.
8. Reed GB, Cox AJ. The human liver after radiation injury. A form of veno-occlusive disease. Am J Pathol 1966;48:597-611.
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
10. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421-30.
11. Lencioni R, Llovet J. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
12. Vernuccio F, Godfrey D, Meyer M, Williamson H V., Salama JK, et al. Local tumor control and patient outcome using stereotactic body radiation therapy for hepatocellular carcinoma: iRECIST as a potential substitute for traditional criteria. Am J Roentgenol 2019;213:1232-9.
13. Price TR, Perkins SM, Sandrasegaran K, Henderson MA, Maluccio MA, et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer 2012;118:3191-8.
14. Mannina EM, Cardenes HR, Lasley FD, Goodman B, Zook J, et al. Role of Stereotactic body radiation therapy before orthotopic liver transplantation: retrospective evaluation of pathologic response and outcomes. Int J Radiat Oncol 2017;97:931-8.
15. Takamatsu S, Kozaka K, Kobayashi S, Yoneda N, Yoshida K, et al. Pathology and images of radiation-induced hepatitis: a review article. Jpn J Radiol 2018;36:241-56.
16. Lall C, Bhargava P, Sandrasegaran K, Shanbhogue AK, Ramsinghani N, et al. Three-dimensional conformal radiation therapy in the liver: MRI findings along a time continuum. J Comput Assist Tomogr 2015;39:356-64.
17. Park MJ, Kim SY, Yoon SM, Kim JH, Park SH, et al. Stereotactic body radiotherapy-induced arterial hypervascularity of non-tumorous hepatic parenchyma in patients with hepatocellular carcinoma: potential pitfalls in tumor response evaluation on multiphase computed tomography. PLoS One 2014;9:e90327.
18. Kimura T, Takahashi S, Takahashi I, Nishibuchi I, Doi Y, et al. The time course of dynamic computed tomographic appearance of radiation injury to the cirrhotic liver following stereotactic body radiation therapy for hepatocellular carcinoma. PLoS One 2015;10:e0125231.
19. Ronot M, Asselah T, Paradis V, Michoux N, Dorvillius M, et al. Liver fibrosis in chronic hepatitis C virus infection: Differentiating minimal from intermediate fibrosis with perfusion CT. Radiology 2010;256:135-42.
20. Yu JI, Park HC, Lim DH, Choi Y, Jung SH, et al. The role of diffusion-weighted magnetic resonance imaging in the treatment response evaluation of hepatocellular carcinoma patients treated with radiation therapy. Int J Radiat Oncol 2014;89:814-21.
21. Lo CH, Huang WY, Hsiang CW, Lee MS, Lin CS, et al. Prognostic significance of apparent diffusion coefficient in hepatocellular carcinoma patients treated with stereotactic ablative radiotherapy. Sci Rep 2019;9:14157.
22. Lee SM, Kim HS, Lee S, Lee JW. Emerging role of 18 F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma. World J Gastroenterol 2019;25:1289-306.
23. Huang WY, Kao CH, Huang WS, Chen CM, Chang LP, et al. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy. J Nucl Med 2013;54:1710-6.
24. Lu RC, She B, Gao WT, Ji YH, Xu DD, et al. Positron-emission tomography for hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol 2019;25:4682-95.
25. Talbot JN, Fartoux L, Balogova S, Nataf V, Kerrou K, et al. Detection of hepatocellular carcinoma with PET/CT: A prospective comparison of 18F-Fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med 2010;51:1699-706.
26. Wallace MC, Sek K, Francis RJ, Samuelson S, Ferguson J, et al. Baseline and post-treatment 18F-Fluorocholine PET/CT predicts outcomes in hepatocellular carcinoma following locoregional therapy. Dig Dis Sci 2020;65:647-57.
27. Koay EJ, Owen D, Das P. Radiation-induced liver disease and modern radiotherapy. Semin Radiat Oncol 2018;28:321-31.
28. Munoz-Schuffenegger P, Ng S, Dawson LA. Radiation-induced liver toxicity. Semin Radiat Oncol 2017;27:350-7.
29. Zuckerman E, Slobodin G, Sabo E, Yeshurun D, Naschitz JE, Groshar D. Quantitative liver-spleen scan using single photon emission computerized tomography (SPECT) for assessment of hepatic function in cirrhotic patients. J Hepatol 2003;39:326-32.
30. Bowen SR, Chapman TR, Borgman J, Miyaoka RS, Kinahan PE, et al. Measuring total liver function on sulfur colloid SPECT/CT for improved risk stratification and outcome prediction of hepatocellular carcinoma patients. EJNMMI Res 2016;6:57.
31. Kamimura K, Fukukura Y, Yoneyama T, Takumi K, Tateyama A, et al. Quantitative evaluation of liver function with T1 relaxation time index on Gd-EOB-DTPA-enhanced MRI: Comparison with signal intensity-based indices. J Magn Reson Imaging 2014;40:884-9.
32. Haimerl M, Verloh N, Zeman F, Fellner C, Nickel D, et al. Gd-EOB-DTPA-enhanced MRI for evaluation of liver function: Comparison between signal-intensity-based indices and T1 relaxometry. Sci Rep 2017;7:43347.
33. Yoon JH, Lee JM, Kang H, Ahn SJ, Yang H, et al. Quantitative assessment of liver function by using Gadoxetic Acid-enhanced MRI: Hepatocyte uptake ratio. Radiology 2019;290:125-33.
